Altmeyer P, Nolting S, Kuhlwein A, Colli E, Scatigna M
Dermatological Clinic, Bochum University, FRG.
J Int Med Res. 1990 Jan-Feb;18(1):61-7. doi: 10.1177/030006059001800108.
A double-blind clinical trial was performed to evaluate efficacy and tolerance of once-daily 2% fenticonazole compared with 1% cyclopyroxolamine spray applied for 2-4 weeks in 100 patients with cutaneous mycotic lesions. After treatment lasting 21.9 +/- 6.7 or 22.5 +/- 6.2 days, respectively, patients receiving fenticonazole or cyclopyroxolamine had negative microscopic findings and cultures were sterile. Comparable clinical improvement was observed in both treatment groups, with 91.8% and 89.8% of patients, respectively, receiving fenticonazole or cyclopyroxolamine being evaluated as cured or greatly improved. Following a drug-free period, the clinical evaluation of nine (20.9%) patients treated with fenticonazole and 14 (30.4%) treated with cyclopyroxolamine worsened. The incidence of side-effects was low; only one patient withdrew from treatment because of a slight itch. It is suggested that fenticonazole and cyclopyroxolamine are equally effective in eradicating cutaneous mycoses and that their efficacy and tolerance are comparable.
进行了一项双盲临床试验，以评估100例皮肤霉菌病患者每日一次使用2%联苯苄唑与使用1%环吡酮胺喷雾剂治疗2 - 4周的疗效和耐受性。在分别持续21.9 +/- 6.7天或22.5 +/- 6.2天的治疗后，接受联苯苄唑或环吡酮胺治疗的患者镜检结果为阴性，培养无菌。两个治疗组均观察到相似的临床改善，接受联苯苄唑或环吡酮胺治疗的患者分别有91.8%和89.8%被评估为治愈或显著改善。在停药期后，9例（20.9%）接受联苯苄唑治疗的患者和14例（30.4%）接受环吡酮胺治疗的患者临床评估结果恶化。副作用发生率较低；只有1例患者因轻微瘙痒而退出治疗。提示联苯苄唑和环吡酮胺在根除皮肤霉菌病方面同样有效，且它们的疗效和耐受性相当。
